Treating Onychomycosis

American Family Physician,  Feb 15, 2001  by Phillip Rodgers,  Mary Bassler

• E-mail
• Print
• Link

(4.) Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996;35(3 pt 2):S2-5.

(5.) Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998;38(5 pt 3):S32-56.

(6.) Lesher JL. Recent developments in antifungal therapy. Dermatol Clin 1996;14(1):163-9 [Published erratum appears in Dermatol Clin 1996;14(4):xii].

(7.) Ciclopirox (Penlac) nail lacquer for onychomycosis. Med Lett Drugs Ther 2000;42(1080):51-2.

(8.) Trepanier EF, Amsden GW. Current issues in onychomycosis. Ann Pharmacother 1998;32:204-13.

(9.) Gupta AK, Daniel CR 3d. Factors that may affect the response of onychomycosis to oral antifungal therapy. Australas J Dermatol 1998;39:222-4.

(10.) Rezabek GH, Friedman AD. Superficial fungal infections of the skin. Diagnosis and current treatment recommendations. Drugs 1992;43:674-82.

(11.) Hay RJ. Onychomycosis. Agents of choice. Dermatol Clin 1993;11(1):161-9.

(12. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996;23:305-13.

(13.) Gupta AK, Scher RK, Rich P. Fluconazole for the treatment of onychomycosis: an update. Int J Dermatol 1998;37:815-20.

(14.) Roberts DT. Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Dermatology 1997;194(suppl 1):37-9.

(15.) Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatol Clin 1997;15(3):535-44.

(16.) Physicians' desk reference. 54th ed. Montvale, N.J.: Medical Economics, 2000.

(17.) Sporanox product information update. Titusville, N.J.: Janssen Pharmaceuticals, December 10, 1999.

(18.) Del Rosso JQ, Gupta AK. Oral antifungal agents: recognition and management of adverse reactions. Todays Ther Trends 1997;15(2):75-84.

(19.) Hofmann H, Brautigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol 1995;131:919-22.

(20.) Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992;304:1151-4.

(21.) Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis. An overview. Dermatol Clin 1997;15(1):121-35.

(22.) Gupta AK, De Doncker P, Scher RK, Haneke E, Daniel CR 3d, Andre J, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37:303-8.

(23.) De Doncker PD, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycosis: an overview. J Am Acad Dermatol 1997;37:969-74.

(24.) Havu V, Brandt D, Heikkila H, Hollmen A, Oksman R, Rantanen T, et al. A double-blind, randomised study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997;136:230-4.

(25.) De Doncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.